Molecular Crosstalk Between The Renin–Angiotensin–Aldosterone System And Neurotransmitter Dysregulation In Alcohol Withdrawal Syndrome

Abstract

The Renin-Angiotensin-Aldosterone System (RAAS) plays a critical role in the pathophysiology of Alcohol Withdrawal Syndrome (AWS), influencing several physiological processes, including blood pressure regulation, fluid balance, and electrolyte homeostasis. Chronic alcohol consumption can disrupt RAAS, leading to hypertension, electrolyte imbalances, and autonomic dysregulation, which contribute to the severity of AWS symptoms. This interaction between RAAS and the nervous system further complicates the withdrawal process, affecting stress response mechanisms and neurochemical balance. Laboratory findings in AWS often show significant alterations in RAAS components, such as increased levels of renin, angiotensin II, and aldosterone, which are associated with cardiovascular and electrolyte disturbances. To assess the severity of withdrawal, tools like the Clinical Institute Withdrawal Assessment and Prediction of Alcohol Withdrawal Severity Scale help guide therapeutic decisions. Traditional treatment of AWS often focuses on benzodiazepines (BZDs), but the growing understanding of RAAS's role has led to alternative strategies, including the use of RAAS inhibitors, anticonvulsants, and alpha2 agonists. These interventions aim to address RAAS dysregulation and reduce the need for BZDs, potentially minimizing the risk of dependence and adverse effects. Future research should explore the genetic aspects of RAAS in alcohol dependence, investigate RAAS inhibitors for their therapeutic potential in AWS, and assess their long-term impact on relapse prevention. Understanding these mechanisms will pave the way for personalized treatments, improving the management of AWS and reducing the likelihood of recurrence in alcohol-dependent individuals.